// App-Quantinova.ai

TCT-264 : Abluminal biodegradable polymer biolimus-eluting versus durable polymer everolimus-eluting stent in patients with diabetes. 5 years follow-up from the COMPARE II trial.

Researchers

Presenter

  • Valeria Paradies

Principal Investigators

  • George Vlachojannis

  • Sjoerd H. Hofma

  • Mario Togni

  • Nicolas Vazquez

  • Mariano Valdes

  • Vassilis Voudris

  • Ton Slagboom

  • Jean-Jacques Goy

  • Andre Vuilliomenet

  • Antonio Serra

Medical Centers

  • Virgen de la Arrixaca University Hospital. Murcia School of Medi, MURCIA, Spain

  • Maasstad Ziekenhuis, Rotterdam, Netherlands

  • Hospital Clinico Universitario, Santiago De Compostela, Spain

  • Onassis Cardiac Surgery Center, Athens, Greece.

  • Factoid Team/ CRF, New York, New York, United States

  • Spain

  • Kantonsspital Aarau, Zuerich, Switzerland

  • Maasstad Ziekenhuis, Rotterdam, Netherlands

  • Unknown, Lausanne, Switzerland

  • Amphia hospital, Breda, Netherlands

  • Unknown, Alphen aan den Rijn, Netherlands

  • University of Freiburg Medical Center, Freiburg, Germany

  • VUmc, Amsterdam, Netherlands

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Medical Center Leeuwarden, Leeuwarden, Netherlands

Locations

  • Greece

  • Netherlands

  • Spain

  • Switzerland

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Crofelemer

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved